OKYO Pharma Discloses Going Concern Doubt in Interim Results, Despite Recent Cash Raise

summarizeSummary

OKYO Pharma reported interim financial results for the six months ended September 30, 2025, showing increased cash and reduced losses, but explicitly disclosed substantial doubt about its ability to continue as a going concern without additional funding.

check_boxKey Events · Earnings and Guidance · OKYO

• Going Concern Warning Issued

  OKYO Pharma disclosed "substantial doubt about the Group's ability to continue as a going concern" without securing additional funding within the next 12 months, projecting a $4 million cash burn.

• Increased Cash Position

  Cash on hand rose to $4.2 million as of September 30, 2025, up from $1.6 million at March 31, 2025, driven by $4.3 million in financing activities.

• Reduced Comprehensive Loss

  The company reported a total comprehensive loss of $3.0 million for the six months ended September 30, 2025, a slight improvement from $3.2 million in the prior comparable period.

• Operational Milestones Recap

  The report summarized key clinical and regulatory advancements for urcosimod, including FDA Fast Track Designation and positive Phase 2 trial results, which were previously announced.

auto_awesomeAnalysis · OKYO · Life Sciences

This interim report is critical due to the explicit "going concern" warning, which signals significant financial risk and the high likelihood of future dilutive financing. While the company improved its cash position through recent fundraising and reduced its comprehensive loss, the warning indicates that current resources are insufficient to cover projected operating costs for the next 12 months. Investors should anticipate further capital raises, which could lead to share dilution. The positive operational updates, while important for the company's long-term prospects, are largely a reiteration of previously disclosed information and are overshadowed by the immediate financial uncertainty.